Immediate release 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-methyl- 1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide formulation

• 收藏
• 分享

专利权人:

Novartis AG

发明人:

Bhardwaj, Upkar,Bordawekar, Mangesh Sadashiv,Comfort, Ann Reese

申请号：

AU2012339829

公开号：

AU2012339829A1

申请日:

2012.11.12

申请国别(地区):

AU

年份:

2014

代理人:

摘要：

A solid dosage form of nilotinib is disclosed that comprises: (i) a core comprising 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide or a pharmaceutically acceptable salt thereof and excipients； and (ii) at least one polymer, said polymer coating said core, wherein disintegration of said solid dosage form is delayed.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/